| Literature DB >> 35432468 |
Yingying Zhang1,2, Hongyang Wang1,2, Weilong Tu1,2, Sayed Haidar Abbas Raza3, Jianguo Cao1,2, Ji Huang1,2, Huali Wu1,2, Chun Fan4, Shengchang Wang4, Ying Zhao4, Yongsong Tan1,2.
Abstract
The depot differences between Subcutaneous Fat (SAF) and Visceral Fat (VAF) are critical for human well-being and disease processes in regard to energy metabolism and endocrine function. Miniature pigs (Sus scrofa) are ideal biomedical models for human energy metabolism and obesity due to the similarity of their lipid metabolism with that of humans. However, the regulation of differences in fat deposition and development remains unclear. In this study, the development of SAF and VAF was characterized and compared in Bama pig during postnatal development (infancy, puberty and adulthood), using RNA sequencing techniques (RNA-Seq). The transcriptome of SAF and VAF was profiled and isolated from 1-, 3- and 6 months-old pigs and identified 23,636 expressed genes, of which 1,165 genes were differentially expressed between the depots and/or developmental stages. Upregulated genes in SAF showed significant function and pathway enrichment in the central nervous system development, lipid metabolism, oxidation-reduction process and cell adhesion, whereas genes involved in the immune system, actin cytoskeleton organization, male gonad development and the hippo signaling pathway were preferentially expressed in VAF. Miner analysis of short time-series expression demonstrated that differentiation in gene expression patterns between the two depots corresponded to their distinct responses in sexual development, hormone signaling pathways, lipid metabolism and the hippo signaling pathway. Transcriptome analysis of SAF and VAF suggested that the depot differences in adipose tissue are not only related to lipid metabolism and endocrine function, but are closely associated with sexual development and organ size regulation.Entities:
Keywords: Bama pig; insulin response; organ size regulation; subcutaneous fat; transcriptome analysis; visceral fat
Year: 2022 PMID: 35432468 PMCID: PMC9008487 DOI: 10.3389/fgene.2022.844833
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Histological sections of SAF tissue and VAF tissue of pigs during the postnatal stage. (A). H&E staining of SAF tissue and VAF tissue at 1, 3 and 6 months (x400 magnification, scale bar: 20μm); (B,C). Mean adipocyte size of SAF and VAF tissues at the postnatal stage; areas were measured by Images J software for 3 different animals per group (0.122 mm2 total area for each sample). * p < 0.05, ** p < 0.01.
FIGURE 2Gene identification and differentially expressed genes (DEGs) in SAF and VAF tissue from Bama pigs during the postnatal stage. (A) Expressed genes in each fat depot. (B) DEGs in each fat depot (fragments per kilobase of exon model per Million mapped fragments, FPKM) fold-change >2; p < 0.05). (C) Experimental verification of gene expression level using qRT-PCR. Relative expression levels (SAF/VAF) of 10 DEGs verified in 3 months pigs. (D) Experimental verification of gene expression level using qRT-PCR. Relative expression levels (SAF/VAF) of 5 DEGs verified in 3 months-old pigs (n = 3). *Significant (p ≤ 0.05). **Significant (p ≤ 0.01).
FIGURE 3Gene Ontology (GO) enrichment of upregulated genes. GO enrichment of upregulated genes in 1 month SAF (A), 1 month-old VAF (B), 3 months SAF (C), 3 months-old VAF (D), 6 months SAF (E), 6 months VAF (F) groups. The X-axis provides the richness factor, calculated by dividing the upregulated gene number in a given GO term by the total gene number in the term of genome. The size and color of the bubbles represent gene number and enrichment significance according to hypergeometric testing, respectively.
Deposit-specific DEGs enrichment in the lipid metabolic process (SAF-specific), sexual development (VAF-specific), hormone signaling pathway (VAF-specific) and Hippo signaling pathway (VAF-specific) at 3 months.
| Gene ID | Gene symbol | Gene title | log2FC (SF/VAF) |
| FDR | |
|---|---|---|---|---|---|---|
| SAF-specific DEGs enrichment in the lipid metabolic process | ||||||
| 448,985 | CYP7A1 | cytochrome P450, family 7, subfamily A, polypeptide 1 | 3.91 | 0 | 0 | |
| 100,157,318 | APOD | apolipoprotein D-like | 3.03 | 0 | 0 | |
| 396,832 | LEP | leptin | 2.18 | 0 | 0 | |
| 100,516,456 | LIPG | lipase, endothelial | 1.78 | 0 | 0 | |
| 100,155,736 | AACS | acetoacetyl-CoA synthetase | 1.32 | 0 | 0.01 | |
| 100,142,668 | APOE | apolipoprotein E | 1.53 | 0 | 0 | |
| 404,693 | IRS1 | insulin receptor substrate 1 | 1.26 | 0 | 0.05 | |
| 397,576 | CAV1 | caveolin 1, caveolae protein, 22 kDa | 1.03 | 0 | 0.03 | |
| 100,156,545 | LIPA | lipase A, lysosomal acid, cholesterol esterase | 1.00 | 0 | 0.04 | |
| 100,512,686 | TWIST1 | twist basic helix-loop-helix transcription factor 1 | 0.91 | 0 | 0.02 | |
| VAF-specific DEGs enrichment in sexual development | ||||||
| 100,521,236 | HOXA11 | homeobox A11 | −9.88 | 0 | 0 | |
| 397,338 | WT1 | Wilms tumor 1 | −6.66 | 0 | 0 | |
| 100,738,625 | NKX3-1 | NK3 homeobox 1 | −5.25 | 0 | 0.02 | |
| 733,631 | GATA3 | GATA binding protein 3 | −3.64 | 0 | 0 | |
| 100,520,560 | WNT2B | wingless-type MMTV integration site family, member 2B | −2.65 | 0 | 0 | |
| 397,600 | GATA-6 | transcription factor GATA-6 | −2.50 | 0 | 0 | |
| 100,516,027 | SFRP2 | secreted frizzled-related protein 2 | −2.21 | 0 | 0.02 | |
| 100,627,056 | WNT5A | wingless-type MMTV integration site family, member 5A | −2.09 | 0 | 0 | |
| 100,155,189 | TESC | tescalcin | −1.12 | 0 | 0.01 | |
| VAF-specific DEGs enrichment in the hormone signaling pathway | ||||||
| 1.01E+08 | KCNN4 | potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | −8.84 | 0 | 0.01 | |
| 1E+08 | ASGR2 | asialoglycoprotein receptor 2 | −7.29 | 0 | 0.04 | |
| 1E+08 | CACNG6 | calcium channel, voltage-dependent, gamma subunit 6 | −6.66 | 0 | 0.01 | |
| 396,828 | KCNMB1 | potassium large conductance calcium-activated channel, subfamily M, beta member 1 | −4.56 | 0 | 0.01 | |
| 397,081 | PLA2G4F | phospholipase A2, group IVF | −4.43 | 0 | 0.04 | |
| 1.01E+08 | ADCY8 | adenylate cyclase 8 (brain) | −4.26 | 0 | 0 | |
| 1.01E+08 | CACNA1D | calcium channel, voltage-dependent, L type, alpha 1D subunit | −3.73 | 0 | 0 | |
| 396,898 | FXYD2 | FXYD domain containing ion transport regulator 2 | −3.52 | 0 | 0 | |
| 396,856 | MYL9 | myosin, light chain 9, regulatory | −3.31 | 0 | 0 | |
| 1E+08 | CACNA2D2 | calcium channel, voltage-dependent, alpha 2/delta subunit 2 | −3.25 | 0 | 0.01 | |
| 1.01E+08 | DUOXA2 | dual oxidase maturation factor 2 | −2.89 | 0 | 0 | |
| 1.01E+08 | MYLK | myosin light chain kinase | −2.88 | 0 | 0 | |
| 1E+08 | CAMK1G | calcium/calmodulin-dependent protein kinase IG | −2.83 | 0 | 0 | |
| 1.01E+08 | ATP1B2 | ATPase, Na+/K+ transporting, beta 2 polypeptide | −1.93 | 0 | 0.01 | |
| 541,593 | ATP1A2 | ATPase, Na+/K+ transporting, alpha 2 polypeptide | −1.89 | 0 | 0.04 | |
| 1.01E+08 | ATP1B1 | ATPase, Na+/K+ transporting, beta 1 polypeptide | −1.76 | 0 | 0 | |
| 396,848 | MYL6B | myosin light chain 6B-like | −1.56 | 0 | 0.04 | |
| 1.01E+08 | RYR2 | ryanodine receptor 2 (cardiac) | −1.51 | 0 | 0.02 | |
| VAF-specific DEGs enrichment in the Hippo signaling pathway | ||||||
| 1.01E+08 | WWC1 | WW and C2 domain containing 1 | −8.84 | 0 | 0 | |
| 1E+08 | CDH1 | cadherin 1, type 1, E-cadherin (epithelial) | −7.78 | 0 | 0 | |
| 1.01E+08 | WNT16 | wingless-type MMTV integration site family, member 16 | −7.05 | 0 | 0 | |
| 1.01E+08 | RASSF6 | Ras association (RalGDS/AF-6) domain family member 6 | −6.27 | 0 | 0 | |
| 397,668 | AREG | amphiregulin | −6.27 | 0 | 0 | |
| 1.01E+08 | DLG3 | discs, large homolog 3 | −3.86 | 0 | 0 | |
| 1.01E+08 | WNT2B | wingless-type MMTV integration site family, member 2B | −2.65 | 0 | 0 | |
| 1.01E+08 | PRKCZ | protein kinase C, zeta | −2.48 | 0 | 0.01 | |
| 1E+08 | WNT10B | wingless-type MMTV integration site family, member 10B | −2.1 | 0 | 0 | |
| 1.01E+08 | WNT5A | wingless-type MMTV integration site family, member 5A | −2.09 | 0 | 0 | |
| 492,315 | BMP7 | bone morphogenetic protein 7 | −2 | 0 | 0 | |
FIGURE 4Patterns of gene expression and GO or pathway enrichment across the points in SAF and VAF. (A) Patterns across 3 time-points in SAF and VAF inferred by STEM analysis. In each frame, the color lines represent the expression patterns of each gene, whereas the black line represents the expression tendency of all the genes. The number of genes belonging to each pattern was labeled above the frame. (B) GO enrichment analysis of 3 significant clusters in SAF. (C) KEGG enrichment analysis of 3 significant clusters in SAF. (D) GO enrichment analysis of 4 significant clusters in VAF. (E) KEGG enrichment analysis of 4 significant clusters in VAF. The significance of the most represented GO-slims in each main cluster is indicated by p-value. The red areas represented the significant p-value, wheaeas the dark gray represented the nonsignificant values.
FIGURE 5Experimental verification of gene expression level in across 3 time-points in SAF and VAF using qRT-PCR(n = 3). A total of 9 genes in profile 7 of VAF and profile 0, 1 and 3 of SAF were randomly selected for qRT-PCR verification. **Difference is extremely significant (p ≤ 0.01).
FIGURE 6Molecular networks functionally associated with lipid metabolism and hormone signaling identified by Ingenuity Pathway Analysis (IPA).